Spotlight on the HOMA2 Triad: Insulin Resistance, Beta Cell Function, and Peripheral Insulin Sensitivity

This Spotlight Article examines how HOMA2-IR, HOMA2-%B, and HOMA2-%S come together to create an assessment matrix that can identify 5 different glucose dysregulation patterns; patterns that are indistinguishable from one another on a routine glucose test.

Introduction

When reviewing fasting insulin, fasting glucose, and a calculated HOMA-IR value, healthcare providers typically evaluate each of these values independently and compare each to their respective established cutoffs. There is very rarely any guidance on how to correlate multiple individual values. Most clinical information is lost in assessing a fasting metabolic panel.

HOMA2 is the University of Oxford's updated model for evaluating glucose regulation. As opposed to using a single formula to calculate values, HOMA2 uses nonlinear computations to generate three related values HOMA2-IR (insulin resistance), HOMA2-%B (beta-cell output) and HOMA2-%S (peripheral insulin sensitivity) from one fasting blood sample.

Each individual metric offers minimal insight. However, evaluated together in an assessment matrix, they differentiate 5 distinct glucose dysregulation patterns -- ranging from reactive hypoglycemia to early and late insulin resistance to type 2 diabetes to type 3c (pancreatogenic) diabetes. The matrix was described by Dr. Brad Rachman on episode 5 of the Optimal DX podcast and represents one of the least commonly utilized resources available in a typical fasting metabolic panel. Below, we explore how to interpret it.

Biomarker Physiology

Peripheral insulin sensitivity refers to the degree to which peripheral tissue (liver, muscle, adipose) takes up glucose in response to insulin. If peripheral tissues become less responsive to insulin, pancreatic beta cells release more insulin to maintain euglycemia. This compensatory mechanism may persist for many years prior to fasting glucose or hemoglobin A1C moving out of the standard laboratory reference range.

In 1985, Turner et al developed an initial version of the HOMA calculator using a simple linear equation based upon both fasting glucose and insulin levels. The University of Oxford Diabetes Trials Unit subsequently revised the model into HOMA2 in 1998, using a nonlinear computer algorithm as opposed to a predetermined equation. HOMA2 separately assesses both hepatic and peripheral forms of insulin resistance and allows for either insulin or C-peptide (or both) to be entered into the model.

Although C-peptide is co-secreted with insulin at equimolar concentrations and is unaffected by exogenous insulin administration, its longer half-life makes it a preferable indicator of pancreatic secretion compared to insulin alone. Many clinicians, including Dr. Rachman, recommend using C-peptide as the input to the calculator because of this property, especially when managing patients receiving exogenous insulin or those with unpredictable insulin dynamics.

To perform a HOMA2 calculation, you require a pair of fasting blood samples – containing glucose and insulin (or C-peptide). A non-fasting sample renders the results invalid. Additionally, the calculator includes input validation thresholds. For example, the acceptable input range for fasting insulin is 2.9–57.6 µIU/mL, and for C-peptide is 0.6–10.5 ng/mL. Any value falling outside these ranges, or any value collected during a non-fasted state, will prevent a valid result. It is essential to verify this before establishing a trend based on a seemingly anomalous HOMA2 result.

Optimal DX has been granted a license by the University of Oxford to utilize this model. Therefore, HOMA2-IR values generated in the Optimal DX application are not equivalent to HOMA-IR values obtained from a laboratory report or an Internet-based calculator that uses the original linear equation.

Functional Interpretation

Each component in the matrix provides different insight into the same regulatory feedback loop:

HOMA2-IR assesses how difficult it is for the body to maintain normoglycemia. Maintaining HOMA2-IR within accepted limits indicates that peripheral tissues respond appropriately to circulating insulin.

HOMA2-%B quantifies beta-cell secretory output relative to a reference population with normal glucose tolerance. Maintaining HOMA2-%B within acceptable limits indicates that your patient’s beta cells are secreting an adequate amount of insulin for the glucose load being managed, neither excessively nor inadequately.

HOMA2-%S evaluates the sensitivity of peripheral tissue to insulin. Maintaining HOMA2-%S within acceptable limits indicates that peripheral tissues remain responsive to circulating insulin without requiring increasing amounts of beta-cell secretory product to compensate.

None of the three individual metrics provides meaningful data when considered alone. Elevated HOMA2-%B values may indicate healthy beta-cell reserve compensating for early insulin resistance, or diminished beta-cell secretory capacity resulting from a low glucose input (which may occur in a patient with declining beta-cell reserve). To determine whether elevated HOMA2-%B values represent beta-cell dysfunction or simply reflect poor glucose-challenge conditions, it is necessary to evaluate all three metrics collectively (along with glucose and TG).

Framework for Pattern Identification

Below is an example of an assessment matrix that illustrates 5 patterns of glucose dysregulation as identified across glucose and lipid values along with the HOMA2 triad. Qualitative direction is provided; specific functional ranges for each marker are presented in the HOMA2 series found in our Resource Center.

Reactive Hypoglycemia

• Glucose: normal to decreased
• Triglycerides: decreased
• HOMA2-%B: decreased
• HOMA2-%S: increased
• HOMA2-IR: decreased
• LDH: significantly decreased

Early Insulin Resistance

• Glucose: normal to increased
• Triglycerides: increased
• HOMA2-%B: increased
• HOMA2-%S: decreased
• HOMA2-IR: increased
• LDH: no change

Late Insulin Resistance

• Glucose: increased
• Triglycerides: increased
• HOMA2-%B: increased/unchanged/decreased
• HOMA2-%S: significantly decreased
• HOMA2-IR: increased
• LDH: decreased

Type 2 Diabetes

• Glucose: significantly increased
• Triglycerides: significantly increased
• HOMA2-%B: increased/unchanged/decreased
• HOMA2-%S: significantly decreased
• HOMA2-IR: significantly increased
• LDH: significantly decreased

Type 3c Diabetes (Pancreatogenic)

• Glucose: normal to decreased
• Triglycerides: decreased
• HOMA2-%B: increased
• HOMA2-%S: decreased
• HOMA2-IR: decreased
• LDH: markedly decreased
• Additional findings: decreased urinary uric acid, decreased urinary calcium oxalate

The critical distinction lies between Type 2 Diabetes and Type 3c Diabetes. Type 2 Diabetes is a hyperinsulinemic condition. Type 3c Diabetes is a pancreatectally insufficient condition. In Type 3c Diabetes, there is a failure of exocrine and endocrine pancreatic function rather than peripheral resistance; therefore, Type 3c Diabetes exhibits lower insulin resistance (decreased HOMA2-IR) due to lower fasting insulin levels.

It is crucial to examine the elevated level of HOMA2-B% observed in Type 3c Diabetes more closely prior to interpreting it as indicative of preserved beta-cell function. Because HOMA2 calculates B% relative to the glucose input level, an abnormally low glucose input can yield higher-than-normal B% values regardless of whether the actual secretory capacity of the beta-cells is reduced. Patients with histories consistent with exocrine pancreatic failure should have their elevated levels of B% examined in conjunction with their low IR levels as evidence supporting investigation of their potential pancreatic insufficiency.

Clinical Application

Patients exhibiting signs of Early Insulin Resistance most often present with normal or near-normal fasting glucose levels but experience fatigue, afternoon energy crashes, brain fog, and other symptoms. Serial increases in fasting insulin levels in patients whose glucose levels remain within normal limits are a good indication that further testing with the full HOMA2 matrix would be beneficial rather than waiting until their glucose or A1C moves out of range.

Patients presenting with Reactive Hypoglycemia most often exhibit normal-to-low fasting glucose values; however, they exhibit symptoms such as shakes, irritability, and/or necessity to consume food regularly throughout the day to avoid symptoms, specifically after consuming food.

The Type 3c Diabetes pattern can be easily missed because an elevated HOMA2-IR level falsely reassures clinicians of the absence of underlying pathophysiology. Clinicians investigating patients having histories consistent with exocrine pancreatic pathology, unexplained fluctuations in glucose, and/or a low level of HOMA2-IR that does not align with expected changes in plasma insulin concentration should consider examination of their pancreatic function beyond merely determining their insulin resistance.

Intervention Strategies

The strategies listed below are relevant for Early Insulin Resistance; Late Insulin Resistance; & Type 2 Diabetes, as these are primarily driven by peripheral insulin resistance:

Dietary:

• Reduce glycemic index; focus on carbohydrate quality vs elimination
• Consume protein at each meal; this reduces postprandial demand for insulin
• Consume fiber sufficient to delay glucose absorption
• Establish consistent meal times; irregular eating habits can exacerbate complications associated with decreased HOMA2-S%

Supplementation:

• Chromium picolinate & alpha-lipoic acid; enhance insulin sensitivity
• Berberine: effective for regulating glucose & insulin levels; use as indicated
• Magnesium acts as a cofactor in glycolysis & is commonly deficient in individuals with insulin resistance
• Correct deficiencies in 25-OH vitamin D; a negative correlation exists between vitamin D status & HOMA2-IR

Physical Activity:

• Regular aerobic exercise & resistance training enhance peripheral sensitivity to insulin
• Improve consistency in sleep schedule; disturbed sleep negatively impacts insulin sensitivity
• Manage stress effectively; chronic elevation in cortisol negatively impacts insulin sensitivity

Monitoring and Follow-up

The three HOMA2 indices should be reviewed alongside fasting glucose and triglycerides. Review them as a matrix, using the same fasting draw used to obtain glucose, insulin, or C-peptide values. Trends in the entire matrix may indicate changes in your patients' condition earlier than trends in individual measurements will. In addition, review the matrices every 3 to 6 months, or immediately if you make some other change to your treatment plan.

Monitoring and Follow-Up

Recheck all three HOMA2 indices together, along with fasting glucose and triglycerides, from the same fasting paired draw used for the original glucose and insulin or C-peptide values. Trend the full matrix as a set rather than tracking any one value in isolation. A shift in the pattern, particularly a HOMA2-%B that stops rising or starts to fall in a patient with an insulin-resistance pattern, often appears before fasting glucose or A1c change. Reassessing every 3 to 6 months, or sooner after a significant change in intervention, provides enough time for a genuine trend to emerge without overtesting.

Conclusion

When reviewing HOMA2-IR, HOMA2-%B, and HOMA2-%S, in combination with glucose and triglyceride values, you are able to determine five different types of glucose regulation disorders which cannot be determined by a simple glucose panel. For example, there is a clear difference between type 2 diabetes and type 3c diabetes. These two disorders can appear very similar when evaluating the results of a basic panel; however, they clearly represent two different clinical paths when reviewing the full matrix of HOMA2 indexes. This represents the type of pattern recognition that is designed into Functional Blood Chemistry Analysis (FBCA): values that appear equivalent when viewed individually become distinguishable clinically when evaluated collectively.

Explore the Full HOMA2 Series with Optimal DX

Optimal DX members get the complete HOMA2 series in the Resource Center, including functional ranges for each index, expanded pattern breakdowns and case-based interpretation. Dr. Brad Rachman discusses this assessment matrix in more detail in Episode 5 of the Optimal DX podcast.

Explore the HOMA2 series in the Resource Center

Join Optimal DX and get access to the Functional Health Report, the Resource Center library, and hundreds of biomarker guides like this one.

See membership options